HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.
There is a need for new adjuvants that will induce immune responses to subunit vaccines. We show that a short peptide, named Hp91, whose sequence corresponds to an area within the endogenous molecule high mobility group box (HMGB1) protein 1 potentiates cellular immune responses to peptide antigen and cellular and humoral immune responses to protein antigen in vivo. Hp91 promoted the in vivo production of the immunomodulatory cytokines, IFN-γ, TNF-α, IL-6, and IL-12 (p70), as well as antigen-specific activation of CD8+ T cells. These results demonstrate the ability of a short immunostimulatory peptide to serve as an adjuvant for subunit vaccines.
Saenz
R
R
Rebecca and John Moores Cancer Center, University of California San Diego (UCSD), La Jolla, CA 92093, USA.
Souza
C da Silva
Cda S
Huang
C-T
CT
Larsson
M
M
Esener
S
S
Messmer
D
D
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D000906:Antibodies / Q000097:blood; D000941:Antigens / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D002460:Cell Line; D016207:Cytokines / Q000097:blood; D005260:Female; D024243:HMGB1 Protein / Q000276:immunology*; D007111:Immunity, Cellular; D056724:Immunity, Humoral; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000276:immunology; D010455:Peptides / Q000276:immunology*; D013154:Spleen / Q000166:cytology / Q000276:immunology
D000276:Adjuvants, Immunologic; D000906:Antibodies; D000941:Antigens; D016207:Cytokines; D024243:HMGB1 Protein; D010455:Peptides; D010047:Ovalbumin
J Leukoc Biol. 2004 May;75(5):749-55
15075354
Eur J Immunol. 2005 Jul;35(7):2184-90
15915542
Eur J Immunol. 1996 Sep;26(9):2062-6
8814247
Science. 1999 Jun 11;284(5421):1835-7
10364556
J Exp Med. 1993 Oct 1;178(4):1309-20
8376936
Am J Physiol Cell Physiol. 2006 Mar;290(3):C917-24
16267105
Immunol Cell Biol. 2004 Oct;82(5):488-96
15479434
Eur J Immunol. 2008 Aug;38(8):2068-71
18651701
Adv Drug Deliv Rev. 1998 Jul 6;32(3):155-172
10837642
Shock. 2006 Aug;26(2):174-9
16878026
J Leukoc Biol. 2007 Jan;81(1):1-5
17032697
Surgery. 1999 Aug;126(2):389-92
10455911
Int Immunol. 2006 Nov;18(11):1563-73
16966494
Endocr Metab Immune Disord Drug Targets. 2007 Mar;7(1):23-8
17346201
Vaccine. 2003 Sep 8;21(25-26):3503-24
14518430
Arch Immunol Ther Exp (Warsz). 2001;49(3):209-15
11478395
J Immunol. 2004 Jul 1;173(1):307-13
15210788
J Exp Med. 1997 Dec 15;186(12):2075-80
9396779
J Immunol. 2005 Jun 15;174(12):7506-15
15944249
Curr Drug Targets Infect Disord. 2001 Nov;1(3):263-71
12455400
Annu Rev Immunol. 2002;20:709-60
11861616
Annu Rev Immunol. 2003;21:335-76
12524386
Nanomedicine. 2010 Oct;6(5):651-61
20348031
Blood. 2008 Aug 15;112(4):1231-9
18519810
J Biol Chem. 2004 Feb 27;279(9):7370-7
14660645
Nat Rev Drug Discov. 2006 Jun;5(6):471-84
16763660
Shock. 2009 Mar;31(3):280-4
19218854
Pharm Res. 2002 Jun;19(6):715-28
12134940
Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7
9380720
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15553-8
9861007
Cytokine Growth Factor Rev. 2006 Jun;17(3):189-201
16513409
Annu Rev Immunol. 1995;13:29-60
7612225
Cancer Immunol Immunother. 2002 Nov;51(10):521-31
12384803
Nature. 2001 Oct 18;413(6857):732-8
11607032
Vaccine. 2009 May 26;27(25-26):3401-4
19200817
Nat Biotechnol. 2007 Aug;25(8):825-6
17687345
Immunol Today. 1993 Jun;14(6):281-4
8104409
Nat Biotechnol. 1999 Nov;17(11):1075-81
10545912
J Biol Chem. 2002 Oct 11;277(41):38635-46
12167613
J Exp Med. 2001 Sep 17;194(6):863-9
11561001
Eur J Immunol. 2001 Oct;31(10):3026-37
11592079
Vaccine. 1995 Oct;13(14):1263-76
8585280
EMBO Rep. 2004 Aug;5(8):825-30
15272298
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2574-9
18256187
Dev Biol Stand. 1998;92:13-7
9554255
J Exp Med. 2007 Nov 26;204(12):2913-23
17984303
J Exp Med. 1997 Nov 17;186(10):1623-31
9362523
Nature. 2002 Jul 11;418(6894):191-5
12110890